de Jong S - Search Results

1

Translating TRAIL-receptor targeting agents to the clinic.

den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, de Vries EG. den Hollander MW, et al. Among authors: de vries eg, de jong s. Cancer Lett. 2013 May 28;332(2):194-201. doi: 10.1016/j.canlet.2012.04.007. Epub 2012 Apr 21. Cancer Lett. 2013. PMID: 22531313 Review.

2

Increased sensitivity of an adriamycin-resistant human small cell lung carcinoma cell line to mitochondrial inhibitors.

de Jong S, Holtrop M, de Vries H, de Vries EG, Mulder NH. de Jong S, et al. Among authors: de vries h, de vries eg. Biochem Biophys Res Commun. 1992 Jan 31;182(2):877-85. doi: 10.1016/0006-291x(92)91814-7. Biochem Biophys Res Commun. 1992. PMID: 1310401

3

Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.

de Jong S, Zijlstra JG, Mulder NH, de Vries EG. de Jong S, et al. Among authors: de vries eg. Cancer Chemother Pharmacol. 1991;28(6):461-4. doi: 10.1007/BF00685823. Cancer Chemother Pharmacol. 1991. PMID: 1657425

4

P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.

van der Zee AG, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PH, Zijlstra JG, de Vries EG. van der Zee AG, et al. Among authors: de vries eg, de jong s. Cancer Res. 1991 Nov 1;51(21):5915-20. Cancer Res. 1991. PMID: 1682037

5

NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell line.

de Jong S, Mulder NH, de Vries EG, Robillard GT. de Jong S, et al. Among authors: de vries eg. Br J Cancer. 1991 Feb;63(2):205-12. doi: 10.1038/bjc.1991.50. Br J Cancer. 1991. PMID: 1847646 Free PMC article.

6

Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

de Jong S, Zijlstra JG, de Vries EG, Mulder NH. de Jong S, et al. Among authors: de vries eg. Cancer Res. 1990 Jan 15;50(2):304-9. Cancer Res. 1990. PMID: 1967222

7

Topoisomerases, new targets in cancer chemotherapy.

Zijlstra JG, de Jong S, de Vries EG, Mulder NH. Zijlstra JG, et al. Among authors: de vries eg, de jong s. Med Oncol Tumor Pharmacother. 1990;7(1):11-8. doi: 10.1007/BF03000485. Med Oncol Tumor Pharmacother. 1990. PMID: 2160032 Review.

8

Detection of DNA cross-links in tumor cells with the ethidium bromide fluorescence assay.

de Jong S, Zijlstra JG, Timmer-Bosscha H, Mulder NH, de Vries EG. de Jong S, et al. Among authors: de vries eg. Int J Cancer. 1986 Apr 15;37(4):557-61. doi: 10.1002/ijc.2910370414. Int J Cancer. 1986. PMID: 3007375

9

Different type of DNA damage caused by three aziridinyl substituted cyclophosphazenes in a human small cell lung carcinoma cell line.

Zijlstra JG, de Jong S, van de Grampel JC, de Vries EG, Mulder NH. Zijlstra JG, et al. Among authors: de vries eg, de jong s. Cancer Res. 1986 Jun;46(6):2726-9. Cancer Res. 1986. PMID: 3008999

10

Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.

van der Zee AG, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EG. van der Zee AG, et al. Among authors: de vries eg, de jong s. Cancer Res. 1994 Feb 1;54(3):749-55. Cancer Res. 1994. PMID: 8306337

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

830 results

Search Page